.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

McKesson
Julphar
Fuji
Novartis
US Army
Cerilliant
Colorcon
Cantor Fitzgerald
Harvard Business School
Chinese Patent Office

Generated: September 24, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Claims for Patent: ► Subscribe

Title:Method for treating abdominal discomfort
Abstract:A method for treating irritable bowel syndrome in a mammalian subject includes administering an effective amount of 13,14-dihydro-15-keto-16,16-difluoro-18-methyl-prostaglandin E.sub.1 or 13,14-dihydro-15-keto-16,16-difluoro-prostaglandin E.sub.1, or a salt, ether, ester or amide thereof, to the subject. A method for treating abdominal discomfort associated with irritable bowel syndrome in a mammalian subject includes administering an effective amount of 13,14-dihydro-15-keto-16,16-difluoro-18-methyl-prostaglandin E.sub.1 or 13,14-dihydro-15-keto-16,16-difluoro-prostaglandin E.sub.1, or a salt, ether, ester or amide thereof, to the subject.
Inventor(s): Ueno; Ryuji (Montgomery, MD), Kuno; Sachiko (Montgomery, MD)
Assignee: Sucampo AG (Zug, CH)
Application Number:10/745,689
Patent Claims: 1. A method for treating irritable bowel syndrome in a mammalian subject, which comprises administering an effective amount of 13,14-dihydro-15-keto-16,16-difluoro-18-methyl-prostaglandin E.sub.1, or a salt, ether, ester or amide thereof, to the subject.

2. The method as described in claim 1, which comprises administering an effective amount of 13,14-dihydro-15-keto-16,16-difluoro-18-methyl-prostaglandin E.sub.1, or a pharmaceutically acceptable salt, ester or amide thereof.

3. The method as described in claim 1, which comprises systemic administration 1-4 times per day or continuous administration in the amount of 0.01-100 .mu.g/kg per day or a 13,14-dihydro-15-keto-16,16-difluoro-18-methyl-prostaglandin E.sub.1 compound.

4. A method for treating as described in claim 2, wherein the administration is in the amount of 0.1-10 .mu.g/kg per day.

5. The method as described in claim 1, which comprises systemic administration 1-4 times per day or continuous administration at the amount of 0.01-100 .mu. g/kg per day.

6. The method as described in claim 5, wherein the administration is at the amount of 0.1-10 .mu.g/kg per day.

7. A method for treating irritable bowel syndrome in a mammalian subject, which comprises administering an effective amount of 13,14-dihydro-15-keto-16,16-difluoro prostaglandin E.sub.1 or a salt, ether, ester or amide thereof, to the subject.

8. The method as described in claim 7, which comprises administering an effective amount of 13,14-dihydro-15-keto-16,16-difluoro-prostaglandin E.sub.1, or a pharmaceutically acceptable salt, ester or amide thereof.

9. The method for treating irritable bowel syndrome in a as described in claim 8, which comprises systemic administration 1-4 times per day or continuous administration in the amount of 0.01-100 .mu.g/kg per day.

10. The method as described in claim 8, wherein the administration is in the amount of 0.1-10 .mu.g/kg per day.

11. The method as described in claim 7, which comprises systemic administration 1-4 times per day or continuous administration at the amount of 0.01-100 .mu.g/kg per day.

12. The method as described in claim 7, wherein the administration is at the amount of 0.1-10 .mu.g/kg per day.

13. A method for treating abdominal discomfort associated with irritable bowel syndrome in a mammalian subject, which comprises administering an effective amount of 13,14-dihydro-15-keto-16,16-difluoro-18-methyl-prostaglandin E.sub.1, or a salt, ether, ester or amide thereof, to the subject.

14. The method as described in claim 13, which comprises administering an effective amount of 13,14-dihydro-15-keto-16,16-difluoro-18-methyl-prostaglandin E.sub.1, or a pharmaceutically acceptable salt, ester or amide thereof.

15. The method as described in claim 14, which comprises systemic administration 1-4 times per day or continuous administration in the amount of 0.01-100 .mu.g/kg per day.

16. The method as described in claim 13, which comprises systemic administration 1-4 times per day or continuous administration in the amount of 0.01-100 .mu.g/kg per day.

17. The method as described in claim 13, wherein the administration is in the amount of 0.1-10 .mu.g/kg per day.

18. A method for treating abdominal discomfort associated with irritable bowel syndrome in a mammalian subject, which comprises administering an effective amount of 13,14-dihydro-15-keto-16,16-difluoro prostaglandin E.sub.1, or a salt, ether, ester or amide thereof, to the subject.

19. The method as described in claim 18, which comprises administering an effective amount of 13,14-dihydro-15-keto-16,16-difluoro-prostaglandin E.sub.1, or a pharmaceutically acceptable salt, ester or amide thereof.

20. The method as described in claim 19, which comprises systemic administration 1-4 times per day or continuous administration in the amount of 0.01-100 .mu.g/kg per day.

21. The method as described in claim 18, which comprises systemic administration 1-4 times per day or continuous administration in the amount of 0.01-100 .mu.g/kg per day.

22. The method as described in claim 18, wherein the administration is in the amount of 0.1-10 .mu.g/kg per day.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Express Scripts
Deloitte
Accenture
Dow
Baxter
UBS
Harvard Business School
AstraZeneca
Queensland Health
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot